Ontology type: schema:ScholarlyArticle
2017-05-04
AUTHORSAnna Schuck, Marie-Christine Goette, Judith Neukirchen, Andrea Kuendgen, Norbert Gattermann, Thomas Schroeder, Guido Kobbe, Ulrich Germing, Rainer Haas
ABSTRACTAzacitidine has become an available therapy for high-risk myelodysplastic syndromes. Infectious complications (IC) may impede the success of therapy. Since most patients are managed in an outpatient setting, often with low level of clinical and microbiological documentation, the impact of IC remains unclear. We retrospectively evaluated the clinical course of 77 patients with MDS treated with azacitidine between 2004 and 2015 (median age 69 years). Clinical workup included severity and type of IC, days in the hospital and with antimicrobial therapy, response to azacitidine, and overall survival (OS). In total, 614 azacitidine cycles were administered, 81 cycles with at least one IC. The median number of administered cycles was 6 (range 1–43). Median OS after the start of azacitidine was 17 months (range 1–103). Infection rates were higher in the first 3 cycles with bacterial infections leading. The better patients’ hematological response to azacitidine with less IC occurred, and fewer days with antimicrobial treatment were needed. Compared to progressive disease, stable disease made no significant improvement in occurrence of IC and days in the hospital. Older age was associated with more IC and longer time in the hospital. Comorbidities or IPSS-R had no influence on IC. The incidence of IC correlated with hematological response and age. Stable disease led to longer OS, but incidence of IC was comparable to progressive disease and survival seemed to be bought by a considerable number of IC. IC rates were highest in the first 3 cycles. We recommend response evaluation after 4–6 cycles. More... »
PAGES1097-1104
http://scigraph.springernature.com/pub.10.1007/s00277-017-3001-2
DOIhttp://dx.doi.org/10.1007/s00277-017-3001-2
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1085177784
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/28474144
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Clinical Sciences",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Adult",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Aged, 80 and over",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Anti-Infective Agents",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Antimetabolites, Antineoplastic",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Azacitidine",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Bacterial Infections",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Female",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Kaplan-Meier Estimate",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Length of Stay",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Male",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Middle Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Myelodysplastic Syndromes",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Outcome Assessment, Health Care",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Retrospective Studies",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Risk Factors",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstra\u00dfe 5, 40225, D\u00fcsseldorf, Germany",
"id": "http://www.grid.ac/institutes/grid.411327.2",
"name": [
"Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstra\u00dfe 5, 40225, D\u00fcsseldorf, Germany"
],
"type": "Organization"
},
"familyName": "Schuck",
"givenName": "Anna",
"id": "sg:person.07532014665.37",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07532014665.37"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstra\u00dfe 5, 40225, D\u00fcsseldorf, Germany",
"id": "http://www.grid.ac/institutes/grid.411327.2",
"name": [
"Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstra\u00dfe 5, 40225, D\u00fcsseldorf, Germany"
],
"type": "Organization"
},
"familyName": "Goette",
"givenName": "Marie-Christine",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstra\u00dfe 5, 40225, D\u00fcsseldorf, Germany",
"id": "http://www.grid.ac/institutes/grid.411327.2",
"name": [
"Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstra\u00dfe 5, 40225, D\u00fcsseldorf, Germany"
],
"type": "Organization"
},
"familyName": "Neukirchen",
"givenName": "Judith",
"id": "sg:person.0643404664.08",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0643404664.08"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstra\u00dfe 5, 40225, D\u00fcsseldorf, Germany",
"id": "http://www.grid.ac/institutes/grid.411327.2",
"name": [
"Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstra\u00dfe 5, 40225, D\u00fcsseldorf, Germany"
],
"type": "Organization"
},
"familyName": "Kuendgen",
"givenName": "Andrea",
"id": "sg:person.01022105364.01",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01022105364.01"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstra\u00dfe 5, 40225, D\u00fcsseldorf, Germany",
"id": "http://www.grid.ac/institutes/grid.411327.2",
"name": [
"Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstra\u00dfe 5, 40225, D\u00fcsseldorf, Germany"
],
"type": "Organization"
},
"familyName": "Gattermann",
"givenName": "Norbert",
"id": "sg:person.01273447501.34",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01273447501.34"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstra\u00dfe 5, 40225, D\u00fcsseldorf, Germany",
"id": "http://www.grid.ac/institutes/grid.411327.2",
"name": [
"Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstra\u00dfe 5, 40225, D\u00fcsseldorf, Germany"
],
"type": "Organization"
},
"familyName": "Schroeder",
"givenName": "Thomas",
"id": "sg:person.01271136615.68",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01271136615.68"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstra\u00dfe 5, 40225, D\u00fcsseldorf, Germany",
"id": "http://www.grid.ac/institutes/grid.411327.2",
"name": [
"Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstra\u00dfe 5, 40225, D\u00fcsseldorf, Germany"
],
"type": "Organization"
},
"familyName": "Kobbe",
"givenName": "Guido",
"id": "sg:person.01164073234.53",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01164073234.53"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstra\u00dfe 5, 40225, D\u00fcsseldorf, Germany",
"id": "http://www.grid.ac/institutes/grid.411327.2",
"name": [
"Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstra\u00dfe 5, 40225, D\u00fcsseldorf, Germany"
],
"type": "Organization"
},
"familyName": "Germing",
"givenName": "Ulrich",
"id": "sg:person.01362464041.20",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362464041.20"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstra\u00dfe 5, 40225, D\u00fcsseldorf, Germany",
"id": "http://www.grid.ac/institutes/grid.411327.2",
"name": [
"Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Moorenstra\u00dfe 5, 40225, D\u00fcsseldorf, Germany"
],
"type": "Organization"
},
"familyName": "Haas",
"givenName": "Rainer",
"id": "sg:person.01127414674.14",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01127414674.14"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1007/s00277-016-2649-3",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1038586565",
"https://doi.org/10.1007/s00277-016-2649-3"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/bf01703109",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1036298304",
"https://doi.org/10.1007/bf01703109"
],
"type": "CreativeWork"
}
],
"datePublished": "2017-05-04",
"datePublishedReg": "2017-05-04",
"description": "Azacitidine has become an available therapy for high-risk myelodysplastic syndromes. Infectious complications (IC) may impede the success of therapy. Since most patients are managed in an outpatient setting, often with low level of clinical and microbiological documentation, the impact of IC remains unclear. We retrospectively evaluated the clinical course of 77 patients with MDS treated with azacitidine between 2004 and 2015 (median age 69\u00a0years). Clinical workup included severity and type of IC, days in the hospital and with antimicrobial therapy, response to azacitidine, and overall survival (OS). In total, 614 azacitidine cycles were administered, 81\u00a0cycles with at least one IC. The median number of administered cycles was 6 (range 1\u201343). Median OS after the start of azacitidine was 17\u00a0months (range 1\u2013103). Infection rates were higher in the first 3 cycles with bacterial infections leading. The better patients\u2019 hematological response to azacitidine with less IC occurred, and fewer days with antimicrobial treatment were needed. Compared to progressive disease, stable disease made no significant improvement in occurrence of IC and days in the hospital. Older age was associated with more IC and longer time in the hospital. Comorbidities or IPSS-R had no influence on IC. The incidence of IC correlated with hematological response and age. Stable disease led to longer OS, but incidence of IC was comparable to progressive disease and survival seemed to be bought by a considerable number of IC. IC rates were highest in the first 3 cycles. We recommend response evaluation after 4\u20136\u00a0cycles.",
"genre": "article",
"id": "sg:pub.10.1007/s00277-017-3001-2",
"isAccessibleForFree": false,
"isPartOf": [
{
"id": "sg:journal.1358129",
"issn": [
"0939-5555",
"1432-0584"
],
"name": "Annals of Hematology",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "7",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "96"
}
],
"keywords": [
"incidence of IC",
"infectious complications",
"overall survival",
"hematological response",
"stable disease",
"high-risk myelodysplastic syndrome",
"more infectious complications",
"median overall survival",
"longer overall survival",
"success of therapy",
"azacitidine cycles",
"microbiological documentation",
"most patients",
"clinical course",
"azacitidine treatment",
"myelodysplastic syndrome",
"clinical workup",
"retrospective study",
"available therapies",
"outpatient setting",
"antimicrobial therapy",
"median number",
"azacitidine",
"infection rate",
"antimicrobial treatment",
"bacterial infections",
"older age",
"hospital",
"disease",
"response evaluation",
"therapy",
"complications",
"IC rates",
"patients",
"incidence",
"survival",
"age",
"days",
"treatment",
"significant improvement",
"low levels",
"comorbidities",
"response",
"IPSS",
"syndrome",
"workup",
"infection",
"considerable number",
"severity",
"months",
"rate",
"MDS",
"setting",
"course",
"levels",
"long time",
"evaluation",
"start",
"study",
"number",
"occurrence",
"impact",
"cycle",
"improvement",
"documentation",
"types",
"success",
"time",
"influence"
],
"name": "A retrospective study evaluating the impact of infectious complications during azacitidine treatment",
"pagination": "1097-1104",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1085177784"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1007/s00277-017-3001-2"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"28474144"
]
}
],
"sameAs": [
"https://doi.org/10.1007/s00277-017-3001-2",
"https://app.dimensions.ai/details/publication/pub.1085177784"
],
"sdDataset": "articles",
"sdDatePublished": "2022-10-01T06:43",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_757.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1007/s00277-017-3001-2"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00277-017-3001-2'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00277-017-3001-2'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00277-017-3001-2'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00277-017-3001-2'
This table displays all metadata directly associated to this object as RDF triples.
261 TRIPLES
21 PREDICATES
113 URIs
103 LITERALS
24 BLANK NODES